Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
Corroborated by 2 sources from 2 publishers
globalhealth3h ago
TL;DR
A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca, a study found Amgen at ESMO: IMDELLTRA data points to earlier lung cancer use.